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Abstract
Herbal ingredients in a Chinese fufang prescription are often replaced by one or several other herbal combinations.
As there have been very few Chinese herbal patent infringement cases, it is still unclear how the Doctrine of
Equivalents should be applied to determine the scope of ‘equivalents’ in Chinese fufang prescriptions. Case law
principles from cases in other technical areas such as chemical patents and biological drug patents can be
borrowed to ascertain a precise scope of a fufang patent. This article summarizes and discusses several chemical
and biopharmaceutical patent cases. In cases where a certain herbal ingredient is substituted by another herb or a
combination of herbs, accused infringers are likely to relate herbal drug patents to chemical drug patents with
strict interpretation whereas patent owners may take advantage of the liberal application of Doctrine of
Equivalence in biopharmaceutical patents by analogizing the complex nature of herbal drugs with biological drugs.
Therefore, consideration should be given to the purpose of an ingredient in a patent, the qualities when
combined with the other ingredients and the intended function. The scope of equivalents also depends on the
stage of the prior art. Moreover, it is desirable to disclose any potential substitutes when drafting the application.
Claims should be drafted in such a way that all foreseeable modifications are encompassed for the protection of
the patent owner’s intellectual property.
Introduction
In Chinese medicine practice, single herbal ingredient
prescriptions are referred to as danfang whereas multi-
ple herbal ingredients prescriptions are fufang which is
more widely used than danfang due to the synergistic
effects. Many herbal ingredients in a fufang prescription
may be replaced by one or several other herbal combi-
nations without failing to produce similar therapeutic
effects. For example, Rhizoma Coptidis (Huanglian),
Cortex Phellodendri (Huangbai) and Radix Scutellariae
Baicalensis (Huangqin) share similar functions and may
be replaced with each other for clearing heat, drying
dampness, draining fire and relieving toxicity. Ginseng,
when taken orally as adaptogen, aphrodisiac and nour-
ishing stimulant, may be substituted by other herbs in
the ginseng family, such as Dangshen and Huangqi.
The existence of multiple substitutes often makes
patent owners concerned about limiting the scope of
their claims to a particular herbal combination. For
example, if someone obtains a fufang patent X
comprising A, B, C and D, does a composition consist-
ing of A, B, C and P, or a composition consisting of A,
B, C, E and F infringe patent X? The answer to this
hypothetical question depends on how the court inter-
prets the scope of the claim coverage in a fufang patent.
Claim interpretation in general
To ascertain the precise scope of a patent, one must
look at (1) the literal scope of a patent claim and (2) the
scope of claim coverage under the Doctrine of Equiva-
lents. Claim construction analysis begins with the literal
words of the claim, which generally carries their ordin-
ary and customary meanings [1]. The claims ‘must be
read in view of the specification, of which they are a
part’ [2].
The Doctrine of Equivalents extends the patentee’s
right to exclude others from making, using, selling or
importing the patented invention beyond the literal
scope of the claims. Infringement under the Doctrine of
Equivalents is an equitable doctrine devised for ‘situa-
tions where there is no literal infringement but [where]
liability is nevertheless appropriate to prevent what is in
essence a pirating of the patentee’s invention’ [3].
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The principal limitation on the scope of equivalents to
which a patentee may be entitled is prosecution-history
estoppel. The essence of prosecution-history estoppel is
that patent owners may not recapture through litigation
any subject matter they previously surrendered during
prosecution. Prosecution-history estoppel prevents
patent owners from using the doctrine of equivalents
during litigation to argue that the scope of a patent
claim should be interpreted to include subject matter
surrendered in a narrowing amendment or implicitly by
argument [4].
After remand from the Supreme Court construed the
Supreme Court’s decision in Festo VIII, the Federal Cir-
cuit’s decision in Festo Corp. (Festo IX) [5] held that (1)
‘a narrowing amendment made to satisfy any require-
ment of the Patent Act may give rise to an estoppel’ and
(2) that there is a presumption that a narrowing amend-
ment made for a reason of patentability surrenders the
entire territory between the original claim limitation and
the amended claim limitation [6]. A patentee may over-
come that presumption by showing that at the time of
the amendment one skilled in the art could not reason-
ably be expected to have drafted a claim that would
have literally encompassed the alleged equivalent [7].
Application of the Doctrine of Equivalents in
fufang patents
For fufang patents, how the Doctrine of Equivalents will
be applied to determine the scope of an ‘equivalents’ is
still unclear. The court has received very few Chinese
herbal patent infringement cases. As such, one must
borrow case law principles from cases in other technical
areas. The most related technical area probably is che-
mical drug patents, where the Doctrine of Equivalents
has matured. The next related technical area is biologi-
cal drug patents. For the purpose of this article, a few
chemical and biotechnological patent cases are summar-
ized and discussed help the readers understand how the
Doctrine of Equivalents could be applied to Chinese
herbal patents.
Chemical drug patent cases
Chemical drug patents are often interpreted strictly. A
charge of infringement would likely be avoided by any
addition, elimination of an active ingredient, or a change
in their proportions [8]. The courts often find non-
infringement if the ingredient being substituted is new,
performs a substantially different function or is not
known at the date of plaintiff’s patent as a proper sub-
stitute for the one omitted.
One illustrative example is Parmlee Pharmaceutical
Co. v. Zink, which involves United States Patent No.
2,478,182 issued to William V. Consolazio [9]. Parmlee
Pharmaceutical is the exclusive licensee of the patent.
There is only one claim in the patent as follows:
’An internally reinforced sodium chloride tablet
comprising compressed granules of sodium chloride;
and an internally disposed cellular stroma of a thin,
permeable, dialyzing film of a material selected from
the group consisting of cellulose acetate and cellu-
lose nitrate, the cells of said stroma containing said
granules of sodium chloride, whereby the sodium
chloride is rendered slowly available when the tablet
reaches the gastro-intestinal tract, the solution time
of the sodium chloride in said tablet in the gastroin-
testinal fluids being from 60 to 80 minutes for a ten
grain tablet.’
The specification of the patent refers to the use of salt
tablets to combat the ill effects of heat and excessive
sweating. Ingestion of a salt tablet is frequently asso-
ciated with incidence of epigastric discomfort, nausea
and vomiting. A popular theory at the time of the inven-
tion was that quick absorption of the salt tablet would
shorten the irritation time to the gastro-intestinal tract.
The patentee’s innovative concept, however, is that a
slow absorption rate of salt would eliminate the discom-
fort in gastro-intestinal tract entirely. The slow-release
result was accomplished by coating the salt tablet with a
cellular stroma of a film made from cellulose acetate or
cellulose nitrate.
The plaintiff’s product became a commercial success.
The accused tablet conformed in general construction
to the patentee’s tablet and accomplished the same
result. The film employed in the accused infringer’s
tablet, however, was not of ‘the group consisting of cel-
lulose acetate and cellulose nitrate’. The film was,
instead, ‘shellac’.
The accused product is not a literal infringement of
the ‘182 patent, because the patent’s claim was limited
to tablets coated with cellulose acetate or cellulose
nitrate’. The plaintiffs argued that the accused tablets
were equivalents and reasoned that Consolazio’s
approach to controlled release was radically different
from that of the past art, and accordingly, the patent
was entitled to a broad range of equivalents which
would embrace every material which might be used to
form the particular structure, ie a thin permeable dialyz-
ing film disclosed in the patent.
The defendants argued that numerous prior art had
taught what materials could be applied to make the
coating and the use of the word ‘consisting’ in the claim
and its reference to cellulose acetate and cellulose
nitrate was restrictive and operated to exclude all sub-
stances not belonging to that group. The Federal Circuit
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agreed with the defendants that while the coatings per-
formed the same function, so many different coatings
were known prior to the patent’s filing that it would be
inequitable to expand the scope of the claim beyond the
two listed substances. In the light of the prior art, the
court held that ‘the proper range of equivalents for this
patent is a narrow one and ... is of insufficient breadth
to include a substance’ other than the two recited in the
claim [9].
In another case, Tanabe Seiyaku Co., Ltd. v. U.S. Inter-
national Trade Commission, the question of whether
acetone (CH3C( = O)CH3) was equivalent to butanone
(CH3C( = O)CH2CH3) as a solvent for a chemical reac-
tion was argued before the court [10]. The plaintiff’s
patent No. 4, 438, 035 was a process patent claiming a
chemical process for preparing diltiazem hydrochloride,
a pharmaceutical product used to treat various cardio-
vascular diseases. Claim 1 of the ‘035 patent reads: ‘A
method of preparing a benzothiazepine derivative of the
formula (Figure 1) wherein R is a hydrogen or acetyl, or
a pharmaceutically acceptable acid addition salt thereof,
which comprises condensing a compound of the for-
mula (Figure 2) wherein R is the same as defined above,
with 2-(dimethylamino)ethyl halide either in the pre-
sence of potassium hydroxide in acetone or in the pre-
sence of potassium carbonate in a solvent selected from
acetone, lower alkyl acetate, a mixture of acetone and
water and a mixture of lower alkyl acetate and water,
and if required, further converting the product into a
pharmaceutically acceptable acid addition salt thereof.’
The chemical reaction recited in claim 1 is known as
an ‘N-alkylation’ reaction. The five base-solvent combi-
nations disclosed in the ‘035 patent and recited in claim
1 are listed in Table 1. The accused Fermion process
involved performing the N-alkylation reaction in the
presence of the base potassium carbonate and, rather
than acetone, the solvent butanone mixed with water.
As the parties agreed that the use of this base-solvent
combination was not within the literal language of claim
1, the issue became whether the use of butanone in the
Fermion process instead of the acetone in the patent
claim constituted a ‘substantial’ or ‘insubstantial’ differ-
ence between the accused process and the patent.
The defendant presented evidence that duplicating
examples from the patent with butanone instead of acet-
one often gave poor results, while in one case, the result
with butanone was better. A good deal of experimenta-
tion was performed by the defendant while optimizing a
scaled-up reaction, from which the court inferred that
the defendant had designed around, rather than copied,
the patented method, and that butanone and acetone
were not truly interchangeable.
Biological drug patent cases
While chemical drugs are small molecules mostly pro-
duced by chemical synthesis, biological drugs are macro-
molecules consisting of thousands of atoms. They are
made by living cells (bacteria, yeast, animal or human
cells) whose DNA has been modified by introduction of
the gene of interest to synthesize the active component.
The complex structures of biological drugs are often
composed of multiple long chains of amino acids, deri-
vatized by sugar moieties and folded by complex
mechanisms.
Due to its complexity, biological drugs cannot be fully
copied. No two cell lines, developed independently, can
be considered identical. A multiplicity of DNA
Figure 1 The chemical structure of benzothiazepine derivative
in claim 1 of the ‘035 patent.
Figure 2 The chemical structure of the compound for
preparing benzothiazepine derivative in claim 1 of the ‘035
patent.
Table 1 Five base-solvent combinations disclosed in the
‘035 patent
Combination Base Solvent
1 potassium hydroxide acetone
2 potassium carbonate acetone
3 potassium carbonate acetone and water
4 potassium carbonate lower alkyl acetate
5 potassium carbonate lower alkyl acetate and water
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sequences encodes the same protein. One or several
amino acid additions, substitutions or deletions can be
made in one protein sequences with retention of the
desired activity. As a consequence, the term ‘biosimilar’
is used to acknowledge the fact that while biosimilar
products are similar to the original product, they are
not exactly the same.
Compared to the chemical drug patents, claims for
biological drug patents are interpreted more broadly.
The courts have applied the Doctrine of Equivalents
more liberally [11]. When deciding whether the accused
drug is a ‘functional equivalent’ of the patented drug,
‘similarities’ between the accused drug with the patented
item are compared, rather than structural identity. Does
the accused drug exert the same therapeutic effects? Are
the structures of the active residuals identical? Does the
accused drug trigger the same immunogenic response?
A sequence with a silent nucleotide substitution, ie one
that produces no alteration in the amino acids sequence
of the expressed protein, will always be an infringement
under the Doctrine of Equivalents [12].
On the other hand, if the difference between the
patented compound and the accused compound is sub-
stantial and significant, a finding of equivalents might
not sustain [13]. In Genentech, Inc. v. The Wellcome
Foundation, Ltd., Genentech owned three patents,
namely a patent directed to a natural protein extracted
from certain human cancer cells, a patent directed to
the materials needed to produce the natural protein
through recombinant DNA technology and the microor-
ganism or cell culture capable of expressing the protein.
The Wellcome Foundation produced a protein through
recombinant DNA technology. The accused version of
fPA differred by one amino acid in a kringle region,
with a half-life ten times of natural t-PA. Nevertheless,
the accused protein exhibited the same clot dissolving
activity of tPA. A jury at the trial court held that the
accused version infringed Genentch’s patent under the
Doctrine of Equivalents, while concluding that they did
not fall literally within the scope of Genentech’s patent.
The district court holding was reversed by the Federal
Circuit [14]. The court held that a 15% difference of the
amino acids sequnce between the accused protein and
the claims are substantial. More importantly, the
accused proteins did not bind to fibrin in a manner
equivalent to native tPA [14].
Nevertheless, given the impact of the Festo IX [6]
owners of biological patents could end up with undesir-
able claim scope due to untactful claim amendment
during patent prosecution. For any narrowing amend-
ment made after Festo, presumption is that a narrowing
amendment, made for any reasons related to patentabil-
ity, raises a rebuttable presumption that infringement
under the doctrine of equivalents is not available for
subject matter surrendered by the narrowing amend-
ment. To rebut the presumption that estoppel applies,
the patentee must show that either (1) the equivalent
was ‘unforeseeable at the time of the application’; (2)
‘the rationale underlying the amendment [bears] no
more than a tangential relation to the equivalent in
question’ or (3) ‘some other reason suggest[s] that the
patentee could not reasonably be expected to have
described the insubstantial substitute in question’[7].
Therefore, a variety of claims presenting differing nar-
rowing limitations should be included at the time of
drafting the application. Applicants should avoid pre-
senting overly broad claims if the broad claims would
likely be amended during the examination process.
Otherwise, the patent owner may end up with a much
narrower patent which may not be enforceable against a
competitor because of a Festo-type estoppel based on
the narrowing amendment.
For example, in Schwarz Pharma v. Paddock, Schwarz
Pharma owns U.S. Patent 4,743,450 (’the ‘450 patent’)
[15]. The ‘450 patent was entitled ‘Stabilized Composi-
tions’ relating to pharmaceutical compositions contain-
ing Angiotensin Converting Enzyme (ACE) inhibitors
for the treatment of hypertension. The ACE inhibitors
must be combined with stabilizers to avoid degradation,
discoloration and hydrolysis. The ‘450 patent generally
teaches the use of an alkali or alkaline earth metal car-
bonate to inhibit cyclization and discoloration. Claims 1
of the patent reads: ‘A pharmaceutical composition
which contains: (a) a drug component which comprises
a suitable amount of an ACE inhibitor which is suscep-
tible to cyclization, hydrolysis, and discoloration, (b) a
suitable amount of an alkali or alkaline earth metal car-
bonate to inhibit cyclization and discoloration, and (c) a
suitable amount of a saccharide to inhibit hydrolysis’
[15].
Paddock filed abbreviated new drug application
(ANDA) for generic moexipril formulation, using mag-
nesium oxide (MgO) as a stabilizer. Schwarz Pharma
sued Paddock for patent infringement, arguing that
MgO is a foreseeable equivalent of magnesium carbo-
nate described in patent. The District Court of Minne-
sota found non-infringement based on prosecution
history estoppel. Originally, the independent Claim 1
recited ‘an alkali or alkaline earth-metal salt’; however, it
was amended to instead recite ‘an alkali or alkaline
earth metal carbonate’ following the rejection. The court
held that the change in claim language was a narrowing
amendment and presumptively surrendered all metal
containing stabilizers and alkali or alkaline earth metal
salts except alkali and alkaline earth metal carbonates.
The court also held that Schwarz had failed to rebut the
presumption of surrender because magnesium oxide was
a foreseeable equivalent of magnesium carbonate and
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because there was no objectively apparent reason for the
narrowing amendment not directly related to the use of
magnesium oxide. The court thus concluded that the
Paddock drug did not infringe because Schwarz was
estopped from claiming that the magnesium oxide used
by Paddock was the equivalent of an alkali or alkaline
earth metal carbonate. The decision was later confirmed
by the Federal Circuit.
Chinese herb patents
As very few herbal patent infringement cases have been
decided by the court, how the Doctrine of Equivalents
will be applied in herbal patents is unclear. Both patent
owners and the accused infringers would have to refer
to case law principles from chemical and/or biological
patent cases.
As the active ingredients identified in herbal medi-
cines are mostly small molecules, it is reasonable that
herbal patents should follow the general rule for chemi-
cal drugs. The accused infringers are likely to argue that
the substituted herbal ingredient adds new chemical
compounds into the drug composition, thereby perform-
ing different functions. Herbal drug patent owners,
nevertheless, may argue that herbal drugs are very dif-
ferent from chemical drugs due to the complex nature
of herbal drugs. Herbal drugs often contain multiple
active ingredients; furthermore, a fufang herbal drug
often includes over a dozen herbs. The complexity of an
herbal drug is further enhanced by the production pro-
cess. As such, every herbal drug can be considered
unique and this is very similar to biological drugs. Sub-
stituting or changing the amount of a minor herbal
component in a fufang drug will lead to a ‘different’
composition but the change may or may not cause dif-
ference in the overall therapeutic effect. Therefore,
‘similarities’ rather than ‘identity’ should be compared.
Unless the ‘similarities’ of the herbal drugs are changed,
the substitute should be considered as an ‘equivalent’
and within the scope of the claims.
For example, substitution of a principal herbal ingredi-
ent in a fufang drug may alter its therapeutic effects and
potential side effects. The original patented fufang com-
position and the substituted fufang should not be con-
sidered as ‘equivalents’. However, minor distinctions (eg
ratio of composites, manufacturing process) should be
recognized under these circumstances. Another impor-
tant factor is whether persons reasonably skilled in the
art would have known of the interchangeability of the
substituting ingredient [9].
The best time to protect the patent owner’s intellec-
tual property is at the time of drafting the application.
While it is impossible to cover all possible equivalents,
it is advisable to disclose any potential substitutes.
Claims should be drafted to literally encompass all
foreseeable modifications. The specification should also
disclose any ‘functional equivalents’ at the time of draft-
ing. The applicant must define exactly which variations
may be included, possibly based on some experimental
result and clinical data [16].
Concluding remarks
In drafting a patent application for a Chinese herbal
drug, one should give consideration to the intended pur-
pose of an ingredient, the quality when combined with
the other ingredients and the intended function. What
constitutes an equivalent must be determined against
the context of the patent, the prior art and the particu-
lar circumstances of the case. The range of equivalents
is broader in an uncrowded art and narrower in a
crowded one.
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